Medullary thyroid carcinoma and biomarkers: Past, present and future

Journal of Internal Medicine

Volumn 266, Issue 1, 2009, Pages 126-140

  Van Veelen, W ^a,b   De Groot, J W B ^c   Acton, D S ^b   Hofstra, R M W ^c   Hoppener J W M ^b   Links, T P ^c   Lips, C J M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Biomarker; Doubling time; Imaging; Prognosis; RET; Targeted therapy

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6 FLUORODOPA F 18; ANTIBODY CONJUGATE; AXITINIB; CALCITONIN; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIBODY I 131; CARCINOEMBRYONIC ANTIGEN; CEP 751; CHOLECYSTOKININ B RECEPTOR; DOTATOC Y 90; FLUORODEOXYGLUCOSE F 18; GASTRIN RECEPTOR; GELATINASE A; IMATINIB; LABETUZUMAB; LESTAURTINIB; MOTESANIB; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; PROTEIN TYROSINE KINASE INHIBITOR; RPI 1; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SORAFENIB; SUNITINIB; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ADVANCED CANCER; CALCITONIN BLOOD LEVEL; CANCER DIAGNOSIS; CANCER GROWTH; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS; MOLECULAR IMAGING; ONCOGENE RET; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; SOMATIC MUTATION; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID SCINTISCANNING; THYROIDECTOMY;

CARCINOMA, MEDULLARY; HUMANS; MEDICAL ONCOLOGY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 66849087637     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2009.02106.x     Document Type: Conference Paper

References (136)

1. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001 86 : 5658 71.
2. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006 27 : 535 60.
3. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005 5 : 367 75.
4. Traugott A, Moley JF. Medullary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol 2005 6 : 339 46.
5. Greene FLP DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (eds.). AJCC Cancer Staging Manual. Thyroid Gland. Philadelphia : Lippincott Raven Publishers, 1997.
6. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000 88 : 1139 48.
7. Modigliani E, Cohen R, Campos JM et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 1998 48 : 265 73.
8. Pelizzo MR, Boschin IM, Bernante P et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 2007 33 : 493 7.
9. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006 107 : 2134 42.
10. Cupisti K, Wolf A, Raffel A et al. Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution's experience over 20 years. Ann Surg 2007 246 : 815 21.
11. de Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter WJ, Links TP. Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf) 2006 65 : 729 36.
12. Moley JF, Fialkowski EA. Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 2007 31 : 946 56.
13. Fugazzola L, Pinchera A, Luchetti F et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers 1994 9 : 21 4.
14. Pellegriti G, Leboulleux S, Baudin E et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 2003 88 : 1537 42.
15. Scollo C, Baudin E, Travagli JP et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003 88 : 2070 5.
16. Franc S, Niccoli-Sire P, Cohen R et al. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2001 55 : 403 9.
17. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol 2007 52 : 1601 9.
18. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001 69 : 89 95.
19. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996 88 : 1456 66.
20. Wang TS, Ocal IT, Sosa JA, Cox H, Roman S. Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma. Thyroid 2008 18 : 889 94.
21. Dora JM, Canalli MH, Capp C, Punales MK, Vieira JG, Maia AL. Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature. Thyroid 2008 18 : 895 9.
22. Costante G, Meringolo D, Durante C et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007 92 : 450 5.
23. Elisei R, Bottici V, Luchetti F et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004 89 : 163 8.
24. Hahm JR, Lee MS, Min YK et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 2001 11 : 73 80. (Pubitemid 32140448)
25. Papi G, Corsello SM, Cioni K et al. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: a multicenter study. J Endocrinol Invest 2006 29 : 427 37.
26. Karanikas G, Moameni A, Poetzi C et al. Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. J Clin Endocrinol Metab 2004 89 : 515 9.
27. d'Herbomez M, Caron P, Bauters C et al. Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur J Endocrinol 2007 157 : 749 55.
28. Baloch Z, Carayon P, Conte-Devolx B et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003 13 : 3 126.
29. Demers LM, Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (Oxf) 2003 58 : 138 40.
30. Bieglmayer C, Scheuba C, Niederle B, Flores J, Vierhapper H. Screening for medullary thyroid carcinoma: experience with different immunoassays for human calcitonin. Wien Klin Wochenschr 2002 114 : 267 73.
31. Bieglmayer C, Vierhapper H, Dudczak R, Niederle B. Measurement of calcitonin by immunoassay analyzers. Clin Chem Lab Med 2007 45 : 662 6.
32. Cohen R, Campos JM, Salaun C et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab 2000 85 : 919 22.
33. Pomares FJ, Rodriguez JM, Nicolas F et al. Presurgical assessment of the tumor burden of familial medullary thyroid carcinoma by calcitonin testing. J Am Coll Surg 2002 195 : 630 4.
34. Scheuba C, Kaserer K, Weinhausl A et al. Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin tests. Surgery 1999 126 : 1089 95 discussion 96.
35. Machens A, Hauptmann S, Dralle H. Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination? J Clin Endocrinol Metab 2008 93 : 2234 8.
36. Miyauchi A, Onishi T, Morimoto S et al. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 1984 199 : 461 6.
37. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005 90 : 6077 84.
38. Laure Giraudet A, Al Ghulzan A, Auperin A et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008 158 : 239 46.
39. Shively JE, Beatty JD. CEA-related antigens: molecular biology and clinical significance. Crit Rev Oncol Hematol 1985 2 : 355 99.
40. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004 61 : 299 310. (Pubitemid 39287058)
41. Wells SA Jr., Haagensen DE Jr., Linehan WM, Farrell RE, Dilley WG. The detection of elevated plasma levels of carcinoembryonic antigen in patients with suspected or established medullary thyroid carcinoma. Cancer 1978 42 : 1498 503.
42. Rougier P, Calmettes C, Laplanche A et al. The values of calcitonin and carcinoembryonic antigen in the treatment and management of nonfamilial medullary thyroid carcinoma. Cancer 1983 51 : 855 62.
43. Machens A, Ukkat J, Hauptmann S, Dralle H. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg 2007 142 : 289 93 discussion 94.
44. Vuillez JP, Peltier P, Caravel JP, Chetanneau A, Saccavini JC, Chatal JF. Immunoscintigraphy using 111In-labeled F(ab')2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma. J Clin Endocrinol Metab 1992 74 : 157 63.
45. Peltier P, Curtet C, Chatal JF et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 1993 34 : 1267 73.
46. Behr TM, Gratz S, Markus PM et al. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 1997 80 : 2436 57.
47. Barbet J, Peltier P, Bardet S et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med 1998 39 : 1172 8.
48. Lips CJ, Landsvater RM, Hoppener JW et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994 331 : 828 35.
49. Lips CJ, Hoppener JW, Thijssen JH. Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Ann Clin Biochem 2001 38 : 168 79.
50. Carlson KM, Bracamontes J, Jackson CE et al. Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 1994 55 : 1076 82.
51. Rossel M, Schuffenecker I, Schlumberger M et al. Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families. Hum Genet 1995 95 : 403 6.
52. Mulligan LM, Eng C, Healey CS et al. A de novo mutation of the RET proto-oncogene in a patient with MEN 2A. Hum Mol Genet 1994 3 : 1007 8.
53. Schuffenecker I, Ginet N, Goldgar D et al. Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. Am J Hum Genet 1997 60 : 233 7.
54. Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s. Hum Mol Genet 1994 3 : 1259 62.
55. Elisei R, Romei C, Cosci B et al. Ret Genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007 92 : 4725 9.
56. Wiench M, Wygoda Z, Gubala E et al. Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol 2001 19 : 1374 80.
57. Wohllk N, Cote GJ, Bugalho MM et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996 81 : 3740 5.
58. Machens A, Niccoli-Sire P, Hoegel J et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003 349 : 1517 25.
59. Yip L, Cote GJ, Shapiro SE et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 2003 138 : 409 16 discussion 16.
60. Kouvaraki MA, Shapiro SE, Perrier ND et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005 15 : 531 44.
61. Machens A, Dralle H. DNA-based window of opportunity for curative pre-emptive therapy of hereditary medullary thyroid cancer. Surgery 2006 139 : 279 82.
62. Machens A, Dralle H. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 2007 31 : 957 68.
63. Eng C, Mulligan LM. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum Mutat 1997 9 : 97 109. (Pubitemid 27133173)
64. Elisei R, Cosci B, Romei C et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10 years follow up study. J Clin Endocrinol Metab 2007 93 : 682 7.
65. Romei C, Elisei R, Pinchera A et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996 81 : 1619 22.
66. Schilling T, Burck J, Sinn HP et al. Prognostic value of codon 918 (ATG→ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 2001 95 : 62 6.
67. Dvorakova S, Vaclavikova E, Sykorova V et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 2008 284 : 21 7.
68. Zedenius J. Is somatic RET mutation a prognostic factor for sporadic medullary thyroid carcinoma? Nat Clin Pract Endocrinol Metab 2008 4 : 432 3.
69. Kaserer K, Scheuba C, Neuhold N et al. Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients. Am J Surg Pathol 2001 25 : 1245 51.
70. Scheuba C, Kaserer K, Kaczirek K, Asari R, Niederle B. Desmoplastic stromal reaction in medullary thyroid cancer-an intraoperative "marker" for lymph node metastases. World J Surg 2006 30 : 853 9.
71. Koperek O, Scheuba C, Cherenko M et al. Desmoplasia in medullary thyroid carcinoma: a reliable indicator of metastatic potential. Histopathology 2008 52 : 623 30.
72. Murray GI. Matrix metalloproteinases: a multifunctional group of molecules. J Pathol 2001 195 : 135 7.
73. Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003 36 : 128 37.
74. Cavalheiro BG, Junqueira CR, Brandao LG. Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: prognostic implications. Thyroid 2008 18 : 865 71.
75. Giraudet AL, Vanel D, Leboulleux S et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007 92 : 4185 90.
76. Koopmans KP, de Vries EG, Kema IP et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006 7 : 728 34.
77. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006 36 : 228 47.
78. de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004 11 : 786 94.
79. Diehl M, Risse JH, Brandt-Mainz K et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001 28 : 1671 6.
80. Szakall S Jr., Esik O, Bajzik G et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002 43 : 66 71. (Pubitemid 34101190)
81. Iagaru A, Masamed R, Singer PA, Conti PS. Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. Mol Imaging Biol 2007 9 : 72 7.
82. Oudoux A, Salaun PY, Bournaud C et al. Sensitivity and prognostic value of positron emission tomography with f-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 2007 92 : 4590 7.
83. Mucha SA, Kunert-Radek J, Pomorski L. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases. Endokrynol Pol 2006 57 : 452 5.
84. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 2008 49 : 573 86.
85. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001 28 : 64 71. (Pubitemid 32120808)
86. Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007 34 : 1604 9.
87. Koopmans KP, de Groot JW, Plukker JT et al. 18F-Dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 2008 49 : 524 31.
88. Timmers HJ, Kozupa A, Chen CC et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 2007 25 : 2262 9.
89. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006 91 : 498 505. (Pubitemid 43236915)
90. Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH, Hor G. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun 1998 19 : 641 7.
91. Ong SC, Schoder H, Patel SG et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007 48 : 501 7.
92. Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) 2001 54 : 641 9.
93. Mato E, Matias-Guiu X, Chico A et al. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J Clin Endocrinol Metab 1998 83 : 2417 20.
94. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 1996 67 : 644 7.
95. Amiri-Mosavi A, Ahlman H, Tisell LE et al. Expression of cholecystokinin-B/gastrin receptors in medullary thyroid cancer. Eur J Surg 1999 165 : 628 31.
96. Blaker M, de Weerth A, Tometten M et al. Expression of the cholecystokinin 2-receptor in normal human thyroid gland and medullary thyroid carcinoma. Eur J Endocrinol 2002 146 : 89 96. (Pubitemid 34126424)
97. Blaker M, Arrenberg P, Stange I et al. The cholecystokinin2-receptor mediates calcitonin secretion, gene expression, and proliferation in the human medullary thyroid carcinoma cell line, TT. Regul Pept 2004 118 : 111 7.
98. Baudin E, Lumbroso J, Schlumberger M et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996 37 : 912 6.
99. Frank-Raue K, Bihl H, Dorr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1995 42 : 31 7.
100. Gao Z, Biersack HJ, Ezziddin S, Logvinski T, An R. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy. J Cancer Res Clin Oncol 2004 130 : 649 56.
101. Czepczynski R, Parisella MG, Kosowicz J et al. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007 34 : 1635 45.
102. Behr TM, Jenner N, Radetzky S et al. Targeting of cholecystokinin-B/ gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998 25 : 424 30.
103. Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002 32 : 97 109. (Pubitemid 34311076)
104. Gotthardt M, Behe MP, Beuter D et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2006 33 : 1273 9.
105. Behr TM, Behe M, Angerstein C et al. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res 1999 5 : 3124s 38s.
106. Behr TM, Jenner N, Behe M et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999 40 : 1029 44.
107. Behe M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 2002 66 : 399 418.
108. Kwekkeboom DJ, Bakker WH, Kooij PP et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 2000 27 : 1312 7.
109. Jing S, Wen D, Yu Y et al. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 1996 85 : 1113 24.
110. Treanor JJ, Goodman L, de Sauvage F et al. Characterization of a multicomponent receptor for GDNF. Nature 1996 382 : 80 3.
111. Lindahl M, Poteryaev D, Yu L et al. Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells. J Biol Chem 2001 276 : 9344 51.
112. Enokido Y, de Sauvage F, Hongo JA et al. GFR alpha-4 and the tyrosine kinase Ret form a functional receptor complex for persephin. Curr Biol 1998 8 : 1019 22.
113. Osamura RY, Yasuda O, Kawakami T, Itoh Y, Inada K, Kakudo K. Immunoelectron microscopic demonstration of regulated pathway for calcitonin and constitutive pathway for carcinoembryonic antigen in the same cells of human medullary carcinomas of thyroid glands. Mod Pathol 1997 10 : 7 11. (Pubitemid 27090769)
114. Juweid M, Sharkey RM, Swayne LC, Goldenberg DM. Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies. Surgery 1997 122 : 1156 65.
115. de Labriolle-Vaylet C, Cattan P, Sarfati E et al. Successful surgical removal of occult metastases of medullary thyroid carcinoma recurrences with the help of immunoscintigraphy and radioimmunoguided surgery. Clin Cancer Res 2000 6 : 363 71.
116. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984 53 : 278 85.
117. Faik Erdogan M, Gursoy A, Erdogan G, Kamel N. Radioactive iodine treatment in medullary thyroid carcinoma. Nucl Med Commun 2006 27 : 359 62.
118. Fialkowski EA, Moley JF. Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol 2006 94 : 737 47.
119. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 2008 4 : 22 32. (Pubitemid 350291115)
120. Ball DW. Medullary thyroid cancer: therapeutic targets and molecular markers. Curr Opin Oncol 2007 19 : 18 23. (Pubitemid 44885595)
121. Carlomagno F, Santoro M. Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. J Chemother 2004 16 (Suppl 4 49 51. (Pubitemid 40065281)
122. Kodama Y, Asai N, Kawai K et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci 2005 96 : 143 8.
123. Putzer BM, Drosten M. The RET proto-oncogene: a potential target for molecular cancer therapy. Trends Mol Med 2004 10 : 351 7.
124. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of Sorafenib in advanced thyroid cancer. J Clin Oncol 2008 26 : 4714 9.
125. Cohen EE, Rosen LS, Vokes EE et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008 26 : 4708 13.
126. Carlomagno F, Vitagliano D, Guida T et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002 62 : 7284 90.
127. Wells S, You YN, Lakhani V et al. A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. J Clin Oncol (Meeting Abstracts) 2006 24 : 5553.
128. Carlomagno F, Guida T, Anaganti S et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004 23 : 6056 63.
129. Plaza-Menacho I, Mologni L, Sala E et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 2007 282 : 29230 40.
130. Carlomagno F, Anaganti S, Guida T et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006 98 : 326 34.
131. Juweid M, Sharkey RM, Behr T et al. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med 1996 37 : 905 11.
132. Juweid M, Sharkey RM, Behr T et al. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 1995 55 : 5946s 51s.
133. Juweid ME, Hajjar G, Swayne LC et al. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 1999 85 : 1828 42.
134. Chatal JF, Campion L, Kraeber-Bodere F et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006 24 : 1705 11.
135. Vainas I, Koussis C, Pazaitou-Panayiotou K et al. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma. J Exp Clin Cancer Res 2004 23 : 549 59.
136. Bodei L, Handkiewicz-Junak D, Grana C et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 2004 19 : 65 71. (Pubitemid 38352287)